SLC25A37 and liver cancer: To this end, we performed xenograft experiments with human liver cancer cells genetically modified to harbor Cas9-mediated MFRN1 loss-of-function alongside inducible knockdown of MFRN2. Following the establishment of small tumor nodules (100 mm3), we induced MFRN2 knockdown by doxycycline-containing diet and monitored tumor growth over time (Fig. 6a).